Efficacy and Safety of Fluticasone Furoate and Oxymetazoline Nasal Spray: A Novel First Fixed Dose Combination for the Management of Allergic Rhinitis with Nasal Congestion

Figures & data

Table 1 Demographic and Baseline Characteristics of All Enrolled Patients

	FDC Group (N=123)	Fluticasone Group (N=127)
Age (years)	33.9±10.7	34.6±11.8
	(32.0–35.8)	(32.5–36.6)
Gender*
Males (n)	73 (59.3%)	81 (63.8%)
Females (n)	50 (40.7%)	46 (36.2%)
Height (cm)	165.6±7.4	165.8±7.5
	(164.3–166.9)	(164.4–167.1)
Weight (kg)	64.0±8.1	64.4±9.2
	(62.5–65.4)	(62.8–66.0)
BMI (kg/m^2)	23.3±2.2	23.4±2.6
	(22.9–23.7)	(22.9–23.8)
History of Allergic Rhinitis (months)	37.5±26.8	35.5±28.4
	(32.7–42.3)	(30.5–40.4)
Baseline scores
TNSS (Night time)	8.4±1.0 (8.3–8.6)	8.4±0.9 (8.2–8.5)
TOSS (Night time)	3.7±1.8 (3.4–4.1)	3.8±2.0 (3.4–4.1)
TSS (Night time)	12.2±2.1 (11.8–12.5)	12.1±2.4 (11.7–12.5)
TNSS (Day time)	9.3±1.6 (9.1–9.6)	9.4 1.5 (9.1–9.7)
TOSS (Day time)	4.5±2.2 (4.1–4.9)	4.5±2.3 (4.2–4.9)
TSS (Day time)	13.8±3.3 (13.3–14.4)	13.9±3.4 (13.3–14.5)

Notes: Data expressed as mean±SD (95% CI). *Data expressed as n (%).

Figure 1 Flow of patients in the study.

Figure 2 Reduction in night time and day time TNSS in the two groups at end of 3 days, 7 days, 14 days, and 28 days. (A) night time TNSS Score; (B) day time TNSS Score.

Figure 3 Reduction in night time and day time Nasal Congestion Score in the two groups at end of 3 days, 7 days, 14 days, and 28 days.